CJC-1295 research guide for Tréméoc. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers looking for CJC-1295 in Tréméoc rapidly learn that local retail options are all but absent from local stores. The key implication for Tréméoc researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the quality verification approach is the same regardless of where you are. A properly operating CJC-1295 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. What follows is a vendor evaluation and quality guide built specifically around CJC-1295, covering everything a Tréméoc researcher needs to source confidently.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Tréméoc comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Before looking at individual vendors, establish a quality benchmark — so you can identify whether a supplier meets the standard. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. The combination of community reputation data and your own COA analysis is the gold standard for CJC-1295 sourcing — community feedback surfaces systemic problems invisible in one transaction, and vice versa. The dry lyophilised powder of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Tréméoc
COA-verified · International tracking · Research grade
CJC-1295 operates outside the framework of pharmaceutical oversight — researchers should understand that the risk characterisation for this compound is based on preclinical evidence rather than regulated clinical data. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; do not freeze and thaw reconstituted CJC-1295 multiple times by preparing small aliquots before storage. The primary quality-related safety risk in CJC-1295 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the key safeguard. PubMed and bioRxiv represent the most comprehensive research databases for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
